Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults (BOOST-X)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Craig Tuggle, MA
- Telefonnummer: 850-202-4416
- E-mail: ctuggle@ihmc.org
Studiesteder
-
-
Florida
-
Pensacola, Florida, Forenede Stater, 32502
- Florida Institute for Human and Machine Cognition
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Male or female aged 60 years or older
- Free of chronic disease or disorder that would preclude full participation or have the potential to confound results
- No structured exercise program (2 or more bouts/wk) within previous 12 months
- Cognitively capable of providing informed consent
Exclusion Criteria:
- BMI ≥ 30.0 kg/m2
- Neurodegenerative disease
- Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and/or physical performance testing
- Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.
- Resting blood pressure <90/60 mmHg or >160/95 mmHg
- Uncontrolled hypertension
- Any current cardiovascular disease or cardiopulmonary instability
Recent cardiovascular event or procedure within the preceding 6 months
- If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure
- Any mechanical valve replacement that requires continuous warfarin anti-coagulation
- Anemia: Hgb <11.0 (♂),10.0 (♂) gm/dl
- Diabetes with HgbA1c >7.0% or fasting blood glucose ≥ 130 mg/dl
- Liver disease with ALT > 52 U/l)
- Chronic kidney disease (eGFR < 45)
- Any current infectious disease
- Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)
- Life expectancy < 1 year Medications / lifestyle
- Insulin sensitizing/blood glucose lowering agents such as metformin
- Currently on or have used GLP-1 agonist or other metabolic / weight loss drug in previous 12 weeks
- Use of nitrate medications
- High dose statin (≥40 mg/d simvastatin equivalence)
- Chronic corticosteroids
- Testosterone or other anabolic/androgenic hormone therapy
- Lidocaine allergy
- Regular tobacco use and/or vaping > 1/wk
- Use of cannabis > 1/wk
- Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males)
- Use of illicit drugs (e.g., cocaine, opioids)
- Unable to commit to ~4 months required to complete the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Nitrate Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
|
|
Placebo komparator: Placebo Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-deprived, manufacturer-matched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
Manufacturer-matched placebo that is nitrate-depleted beetroot juice (70 ml per drink).
Both nitrate and placebo will be purchased from Beet It.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess the clinical impact of nitrate supplementation on a proportion of older adults attaining exercise-induced health benefits.
Tidsramme: 12 weeks
|
The primary outcome will be assessed using logistic regression with the proportion not attaining Cardiorespiratory Fitness and functional Muscle Quality Minimally Clinical Differences as the response variable and treatment adjusted for sex and age group across the 12 week intervention.
|
12 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cardiorespiratory demand during submaximal cycle exercise.
Tidsramme: 12 weeks
|
Supportive analyses will include secondary (cardiorespiratory demand during submaximal steady state exercise) outcomes.
The steady state exercise cycling will be 10 minutes at 60% of peak power (Watts) during the VO2 peak test.
|
12 weeks
|
|
Neuromuscular fatiguability during isometric holds.
Tidsramme: 12 weeks
|
The knee extensors will perform a 30 second isometric flexion on a dynamometer.
The fatigue will be defined by the force decline across the 30 seconds.
|
12 weeks
|
|
10 meter max gait speed.
Tidsramme: 12 weeks
|
Participants will walk as quickly as possible across a 10 meter, straight course.
Time is recorded for up to three attempts.
A lower time indicates a faster speed.
|
12 weeks
|
|
modified Balance Error Scoring System (mBESS)
Tidsramme: 12 weeks
|
Stability is assessed with the Sway Medical tablet app via three stances: double-leg, single-leg, and tandem.
Scoring is decided by losing balance or opening eyes during closed eyed tests.
|
12 weeks
|
|
NIH PROMIS Physical Function SF
Tidsramme: 12 weeks
|
The NIH PROMIS Physical Function Short Form (SF) is a standardized tool used to evaluate an individual's physical abilities and limitations in daily activities.
It is part of the broader Patient-Reported Outcomes Measurement Information System (PROMIS), which focuses on measuring patient-reported outcomes across various health domains.
|
12 weeks
|
|
NIH PROMIS Fatigue SF
Tidsramme: 12 weeks
|
PROMIS Fatigue SF refers to the short form of the Patient-Reported Outcomes Measurement Information System designed to assess fatigue levels in patients.
It provides a standardized way to measure fatigue, which can be used in various clinical settings to evaluate patient health status.
|
12 weeks
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cognitive function.
Tidsramme: 12 weeks
|
Cognitive function is assessed via Sway Medical reaction time via three assessments: visual processing speed: measures how quickly a person can interpret visual information.
|
12 weeks
|
|
Psychological state.
Tidsramme: 12 weeks
|
Depression and anxiety are assessed via the well-validated Patient Health Questionnaire 9 (PHQ-9) both via Sway.
The PHQ-9, or Patient Health Questionnaire-9, is a tool used to screen for, diagnose, and measure the severity of depression.
It consists of nine questions that assess how often a person has experienced symptoms of depression over the past two weeks.
|
12 weeks
|
|
Sleep quality and nocturnal stress.
Tidsramme: 12 weeks
|
Perceptions of sleep quality are measured using the short forms (SF) of PROMIS Sleep Disturbance and Sleep-Related Impairment.
For direct monitoring, participants wear an Oura Gen-4 ring to quantify sleep behavior with stress monitored via Heart Rate /Heart Rate variability (HRV) across the full enrollment period, as we have done in previous studies including the ongoing NIA M3AX Trial (NCT06507189).
The Oura ring is well validated against polysomnography for several sleep metrics and nocturnal HR/HRV.
|
12 weeks
|
|
Free-living activity via the Oura Gen 4.
Tidsramme: 12 weeks
|
Free-living activity is also monitored daily via the Oura Gen-4 ring worn throughout trial participation.
Variables such as step count and heart rate will used to determine activity.
|
12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IRB-2026-0019
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .